目的 探討核糖核苷酸還原酶亞單位M2（RRM2）在肝細(xì)胞癌組織中的表達(dá)情況及其臨床特征、預(yù)后相關(guān)性。方法 檢索腫瘤基因組圖譜（TCGA）數(shù)據(jù)庫(kù)獲取肝細(xì)胞癌轉(zhuǎn)錄組數(shù)據(jù)和臨床相關(guān)資料數(shù)據(jù)，提取RRM2在肝細(xì)胞癌和癌旁組織中的表達(dá)數(shù)據(jù)，采用COX單因素、多因素分析RRM2與肝細(xì)胞癌患者臨床和預(yù)后相關(guān)性。利用The Human Protein Atlas（HAP）數(shù)據(jù)庫(kù)檢索RRM2蛋白在肝細(xì)胞癌中的表達(dá)情況。結(jié)果 肝細(xì)胞癌組織中RRM2蛋白和mRNA表達(dá)均顯著高于癌旁組織，且Ⅰ、Ⅱ期肝細(xì)胞癌組織中RRM2表達(dá)顯著高于Ⅲ、Ⅳ期癌組織（P<0.01）。RRM2表達(dá)情況與肝細(xì)胞癌患者預(yù)后呈負(fù)相關(guān)（P<0.01）。COX單因素、多因素分析顯示，肝細(xì)胞癌組織中RRM2表達(dá)水平、TNM分期是影響肝細(xì)胞癌預(yù)后的獨(dú)立因素。結(jié)論 RRM2在肝細(xì)胞癌發(fā)生發(fā)展過(guò)程中可能發(fā)揮促進(jìn)作用，是影響肝細(xì)胞癌患者預(yù)后的獨(dú)立危險(xiǎn)因素，其可能成為早期診斷肝細(xì)胞癌的分子標(biāo)志物和判斷預(yù)后的潛在指標(biāo)，為RRM2抑制劑的研發(fā)提供理論基礎(chǔ)。

Objective To investigate the expression of ribonucleotide reductase subunit M2 (RRM2) gene and its prognostic significance in hepatocellular carcinoma (HCC). Methods The HCC transcriptome data and clinical data from The Cancer Genome Atlas (TCGA) database, the expression data of RRM2 in HCC and adjacent tissues was extracted, and COX single factor and multivariate were used to analyze the clinical and prognostic correlation between RRM2 and HCC patients. The Human Protein Atlas (HAP) database was used to analyze the expression of RRM2 protein in HCC. Results RRM2 protein and mRNA were highly expressed in adjacent tissues, and the expression level of RRM2 in stage Ⅰ and stage Ⅱ HCC tissue was significantly higher than that in stage Ⅲ and stage Ⅳ cancer tissue (P<0.01). Statistical analysis showed that the expression of RRM2 was negatively correlated with the prognosis of HCC patients (P<0.01). COX univariate and multivariate analysis showed that the expression level of RRM2 and TNM stage in HCC tissues were independent factors affecting the prognosis of HCC. Conclusion RRM2 may play a promoting role in the occurrence and development of HCC and is an independent risk factor affecting the prognosis of HCC patients. It may become a molecular marker for early diagnosis of HCC and a potential indicator for prognosis, providing a theoretical basis for the development of RRM2 inhibitors.

R979.1